Browsing by Author Lu, Shun

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Showing results 1 to 20 of 31 next >
Issue Date Title Author(s)
2018 Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung Lu, Shun;Li, Wei;Zhou, Caicun;Hu, Cheng-Ping;Qin, Shukui;Cheng, Gang;Feng, Jifeng;Wang, Jie;Cseh, Agnieszka;Peil, Barbara;Gibson, Neil;Ehrnrooth, Eva;Zhang, Li
20-May-2020 Analysis of canonical and noncanonical splicing site mutation of MET that causes exon 14 skipping. Yu, Yongfeng;Chen, Rongrong;Zhao, Jun;Yi, Xin;Lu, Shun
Apr-2020 Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort Song, Yong;Hu, Chengping;Xie, Zhanhong;Wu, Lin;Zhu, Zhengfei;Rao, Chuangzhou;Liu, Li;Chen, Yuan;Liang, Naixin;Chen, Jun;Hu, Chunhong;Yang, Nong;Hu, Jie;Zhao, Weixin;Tong, Gangling;Dong, Xiaorong;Zheng, Di;Jin, Meiling;Chen, Jianhua;Huang, Meijuan;He, Yong;Rosell, Rafael;Lippi, Giuseppe;Mino-Kenudson, Mari;Han-Zhang, Han;Mao, Xinru;Zhang, Lu;Liu, Hao;Field, John K.;Chuai, Shannon;Ye, Junyi;Han, Yusheng;Lu, Shun
Jul-2022 Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting Ai, Xinghao;Yu, Yongfeng;Zhao, Jun;Sheng, Wang;Bai, Jing;Fan, Zaiwen;Liu, Xuemei;Ji, Wenxiang;Chen, Rongrong;Lu, Shun
2018 A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel Wu, Yi-Long;Wang, Chang-Li;Liao, Mei-Lin;Guan, Zhong-Zhen;Gao, Chen-Yan;Lu, Shun;Zhao, Ming-Fang;Wang, Jie;Liu, Xiao-Qing;Yang, Jin-Ji;Liang, Jun;Mao, Wei-Min;Han, Bao-Hui;Zhang, Xu-Chao;Song, Yong;Feng, Ji-Feng;Ma, Sheng-Lin;Wu, Gang;Zhou, Cai-Cun;Chen, Ke-Neng;Cheng, Ying;He, Yong;Chen, Chun;Wang, Qun;Lin, Ji-Zhen;Zhu, Bo;Liu, Yun-Peng;Hu, Yi;Qiao, Gui-Bin;Zhou, Qing;Song, Qi-Bin;Wu, Nan;Wu, Lin;Huang, Cheng;Fu, Xiao-Long;Xiong, Jian-Ping;Hu, Jie;Hu, Cheng-Ping;Chang, Jian-Hua;Zhao, Qiong;Zhao, Jun;Zhou,
2017 A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel Wu, Yi-Long;Wang, Chang-Li;Sun, Yan;Liao, Mei-Lin;Guan, Zhong-Zhen;Yang, Zhi-Min;Zhou, Qing-Hua;Lu, Shun;Cheng, Ying;Liu, Xiao-Qing;Zhang, Xu-Chao;Zhou, Caicun;Wang, Jie;Zhou, Qing;Song, Yong;Han, Bao-Hui;Ma, Zhi-Yong;Yang, Fan;Wang, Qun;Chuai, Shao-Kun;Shao, Yang;He, Wei;Zhu, Guanshan;Xiong, Lei;Wang, Jian-Jun;Chen, Ke-Neng;Zhang, Li;Mao, Wei-Min;Ma, Sheng-Lin;Feng, Ji-Feng;Yang, Xue-Ning;Xu, Lin;Chen, Gang;Zhao, Jian;Song, Qi-Bin;Shen-Tu, Yang;Qiao, Gui-Bin;Yu, Ding;Yu, Shi-Ying;Hu, Yi;Chen, Ming;Chen, Go
Jul-2021 ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring MET exon 14 skipping alterations (METex14). Yu, Yongfeng;Ren, Yongxin;Fang, Jian;Cao, Lejie;Liang, Zongan;Guo, Qisen;Han, Sen;Ji, Zimei;Wang, Ye;Sun, Yulan;Chen, Yuan;Li, Xingya;Xu, Hua;Zhou, Jianying;Jiang, Liyan;Cheng, Ying;Han, Zhigang;Shi, Jianhua;Chen, Gongyan;Ma, Rui;Fan, Yun;Sun, Sanyuan;Jiao, Longxian;Jia, Xiaoyun;Wang, Linfang;Lu, Puhan;Li, Jing;Xu, Qian;Luo, Xian;Su, Weiguo;Lu, Shun
Jul-2021 D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156). Lu, Shun;Zhang, Yiping;Zhang, Guojun;Zhou, Jianying;Cang, Shundong;Cheng, Ying;Wu, Gang;Cao, Peiguo;Lv, Dongqing;Jin, Xiangming;Jian, Hong;Chen, Chengshui;Jiang, Guanming;Tian, Panwen;Wang, Kai;Zhao, Hui;Chen, Gongyan;Chen, Qun;Ding, Cuimin;Yang, Junquan;Guo, Renhua;Sun, Guoping;Wang, Bin;Jiang, Liyan;Zhuang, Wu;Liu, Zhe;Fang, Jian;Liu, Yunpeng;Zhang, Jian;Chen, Jun;Pan, Yueyin;Yu, Qitao;Zhao, Min;Cui, Jiuwei;Li, Dianming;Yi, Tienan;Yu, Zhuang;Yang, Yan;Zhang, Yan;Zhi, Xiuyi;Huang, Yunchao;Wu, Rong;Chen, Liangan;Zang, Aimin;Cao, Lejie;Li, Qingshan;Li, Xiaoling;Song, Yong;Wang, Donglin;Zhang, Shucai
Aug-2021 Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study Ai, Xinghao;Pan, Yueyin;Shi, Jianhua;Yang, Nong;Liu, Chunling;Zhou, Jianying;Zhang, Xiaodong;Dong, Xiaorong;He, Jianxing;Li, Xiaoling;Chen, Gongyan;Li, Xingya;Zhang, Helong;Liao, Wangjun;Zhang, Yiping;Ma, Zhiyong;Jiang, Liyan;Cui, Jiuwei;Hu, Chunhong;Wang, Wei;Huang, Cheng;Zhao, Jun;Ding, Cuimin;Hu, Xiaohua;Wang, Kai;Gao, Beili;Song, Yong;Liu, Xiaoqing;Xiong, Jianping;Liu, Anwen;Li, Junling;Liu, Zhe;Li, Yinyin;Wang, Mengzhao;Zhang, Biao;Zhang, Dan;Lu, Shun
30-Jun-2023 Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial Lu, Shun;Pan, Hongming;Wu, Lin;Yao, Yu;He, Jianxing;Wang, Yan;Wang, Xiuwen;Fang, Yong;Zhou, Zhen;Wang, Xicheng;Cai, Xiuyu;Yu, Yan;Ma, Zhiyong;Min, Xuhong;Yang, Zhixiong;Cao, Lejie;Yang, Huaping;Shu, Yongqian;Zhuang, Wu;Cang, Shundong;Fang, Jian;Li, Kai;Yu, Zhuang;Cui, Jiuwei;Zhang, Yang;Li, Man;Wen, Xinxuan;Zhang, Jie;Li, Weidong;Shi, Jianhua;Xu, Xingxiang;Zhong, Diansheng;Wang, Tao;Zhu, Jiajia
2011 Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Zhou, Caicun;Wu, Yi-Long;Chen, Gongyan;Feng, Jifeng;Liu, Xiao-Qing;Wang, Changli;Zhang, Shucai;Wang, Jie;Zhou, Songwen;Ren, Shengxiang;Lu, Shun;Zhang, Li;Hu, Chengping;Hu, Chunhong;Luo, Yi;Chen, Lei;Ye, Ming;Huang, Jianan;Zhi, Xiuyi;Zhang, Yiping;Xiu, Qingyu;Ma, Jun;Zhang, Li;You, Changxuan
Apr-2023 Event-free survival (EFS) with neoadjuvant nivolumab (NIVO) plus platinum- doublet chemotherapy (chemo) versus chemo by surgical outcomes in resectable non-small cell lung cancer (NSCLC) from CheckMate 816 Spicer, Jonathan;Wang, Changli;Tanaka, Fumihiro;Chen, Ke-Neng;Ito, Hiroyuki;Liberman, Moishe;Chen, Qixun;Girard, Nicolas;Lu, Shun;Provencio, Mariano;Mitsudomi, Tetsuya;Awad, Mark;Felip, Enriqueta;Swanson, Scott;Forde, Patrick;Cai, Junliang;Mahmood, Javed;Hu, Nan;Tran, Phuong;Broderick, Stephen
2005 Heterogeneity in predisposition of hepatic cells to be induced into pancreatic endocrine cells by PDX-1 Lu, Shun;Wang, Wei-Ping;Wang, Xiao-Fei;Zheng, Zong-Mei;Chen, Ping;Ma, Kang-Tao;Zhou, Chun-Yan
2016 Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer Lu, Shun;Cheng, Ying;Zhou, Cai-cun;Wang, Jie;Yang, James Chih-Hsin;Zhang, Ping-hai;Zhang, Xiao-qing;Wang, Xin;Orlando, Mauro;Wu, Yi-long
2018 Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung - A Multicenter, Open-label, Randomized, Phase III Trial Lu, Shun;Chen, Zhiwei;Hu, Chengping;Zhang, Jian;Chen, Yuan;Song, Yong;Zhao, Qiong;Fan, Yun;Wu, Gang;Ma, Zhiyong;Fang, Jian;Yu, Qitao;Liu, Zhe
Apr-2022 Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer Forde, Patrick M.;Spicer, Jonathan;Lu, Shun;Provencio, Mariano;Mitsudomi, Tetsuya;Awad, Mark M.;Felip, Enriqueta;Broderick, Stephen R.;Brahmer, Julie R.;Swanson, Scott J.;Kerr, Keith;Wang, Changli;Ciuleanu, Tudor-Eliade;Saylors, Gene B.;Tanaka, Fumihiro;Ito, Hiroyuki;Chen, Ke-Neng;Liberman, Moishe;Vokes, Everett E.;Taube, Janis M.;Dorange, Cecile;Cai, Junliang;Fiore, Joseph;Jarkowski, Anthony;Balli, David;Sausen, Mark;Pandya, Dimple;Calvet, Christophe Y.;Girard, Nicolas
Jul-2021 Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial. Forde, Patrick M.;Spicer, Jonathan;Lu, Shun;Provencio, Mariano;Mitsudomi, Tetsuya;Awad, Mark M.;Felip, Enriqueta;Broderick, Stephen;Brahmer, Julie;Swanson, Scott J.;Kerr, Keith;Wang, Changli;Saylors, Gene B.;Tanaka, Fumihiro;Ito, Hiroyuki;Chen, Ke-Neng;Dorange, Cecile;Cai, Junliang;Fiore, Joseph;Girard, Nicholas
2012 Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCL Zhou, Caicun;Wu, Yi Long;Liu, Xiaoqing;Wang, Changli;Chen, Gongyan;Feng, Ji Feng;Zhang, Shucai;Wang, Jie;Zhou, Songwen;Ren, Shengxiang;Lu, Shun;Zhang, Li;Hu, Cheng-ping;Luo, Yi;Chen, Lei;Ye, Ming;Huang, Jianan;Zhi, Xiuyi;Zhang, Yiping;Xiu, Qingyu
20-May-2020 Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). Lu, Shun;Fang, Jian;Li, Xingya;Cao, Lejie;Zhou, Jianying;Guo, Qisen;Liang, Zongan;Cheng, Ying;Jiang, Liyan;Yang, Nong;Han, Zhigang;Shi, Jianhua;Chen, Yuan;Xu, Hua;Zhang, Helong;Zhang, Di;Li, Jing;Wang, Linfang;Ren, Yongxin;Su, Weiguo
20-May-2020 Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC). Wang, Jie;Yu, Xinmin;Lu, Shun;Hu, Yanping;Sun, Yuping;Wang, Zhijie;Zhao, Jun;Yu, Yan;Hu, Chunhong;Yang, Kunyu;Feng, Guosheng;Ying, Kejing;Zhuang, Wu;Zhou, Jianying;Wu, Jingxun;Wu, Yanjie;Lin, Xiao;Liang, Liang;Yang, Nong
Showing results 1 to 20 of 31 next >